Passage Bio, Inc.
-54.4% · 90d
$5.75
-0.09 (-1.54%)
News
(1)April 2026
Passage BIO, Inc. — DEF 14A Filing
PASGPassage BIO, Inc.
# 📄 What This Document Is — Your Company's Annual Report Card This is a **Definitive Proxy Statement (DEF 14A)** for **Passage Bio, Inc. (PASG)**. Think of it as the official "ballot and report card" for the company's annual shareholder meeting. 👉 **Why it exists:** Public companies are legally
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%